2. Academic Validation
  3. Development of a Highly Specific 18F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors

Development of a Highly Specific 18F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors

  • J Med Chem. 2023 Sep 13. doi: 10.1021/acs.jmedchem.3c00735.
Tao Wang 1 2,  Jingqi Wang 1,  Leyuan Chen 3,  Xiaojun Zhang 4,  Tiantian Mou 5,  Xiaodan An 1,  Jinming Zhang 4,  Xiaoli Zhang 5,  Winnie Deuther-Conrad 6,  Yiyun Huang 7,  Hongmei Jia 1
Affiliations

Affiliations

  • 1 Key Laboratory of Radiopharmaceuticals (Beijing Normal University), Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
  • 2 Department of Nuclear Medicine, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
  • 3 Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin 300192, China.
  • 4 Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
  • 5 Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
  • 6 Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 04318 Leipzig, Germany.
  • 7 Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut 06520-8048, United States.
PMID: 37704582 DOI: 10.1021/acs.jmedchem.3c00735
Abstract

Novel ligands with the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 5,6-dimethoxyisoindoline pharmacophore were designed and synthesized for evaluation of their structure-activity relationship to the sigma-2 (σ2) receptor and developed as suitable PET radioligands. Compound 1 was found to possess nanomolar affinity (Ki(σ1) = 2.57 nM) for the σ2 receptor, high subtype selectivity (>2000-fold), and high selectivity over 40 other receptors and transporters. Radioligand [18F]1 was prepared with radiochemical yield of 37-54%, > 99% radiochemical purity, and molar activity of 107-189 GBq/μmol. Biodistribution and blocking studies in mice and micro-PET/CT imaging of [18F]1 in rats indicated excellent binding specificity to the σ2 receptors in vivo. Micro-PET/CT imaging of [18F]1 in the U87MG glioma xenograft model demonstrated clear tumor visualization with high tumor uptake and tumor-to-background ratio. Co-injection with CM398 (5 μmol/kg) led to a remarkable reduction of tumor uptake (80%, 60-70 min), indicating high specific binding of [18F]1 in U87MG glioma xenografts.

Figures
Products